Treatment of Diabetic Foot Ulcer Using Matriderm In Comparison with a Skin Graft

Abstract

BackgroundFor patients with neuropathy, vasculopathy, and impairment of wound healing, treatment of a diabetic foot ulcer poses many challenges. A large number of dermal analogues have been invented in an effort to overcome these challenges. Matriderm, a dermal analogue, is made from bovine collagen and elastin. This study was conducted in order to evaluate the effectiveness of Matriderm for treatment of diabetic foot ulcers, in comparison with skin grafting.MethodsSixty patients with diabetic foot ulcer were included in this prospective study. The average age of the patients, who had type II diabetes mellitus, was 58 years old. The patients were allocated to an experimental or control group with their consents. The patients were selected with their consent for inclusion in an experimental group and a control group. Patients in the experimental group received a Matriderm appliance and a split-thickness skin graft, while those in the control group received only a split-thickness skin graft.ResultsA shorter hospitalization period (7.52 weeks) was observed in the experimental group than in the control group (9.22 weeks), and a shorter period of time (8.61 weeks) was required for complete healing, compared with the control group (12.94 weeks), with statistical significance (P<0.05). A higher elasticity ratio of the affected side to the non-affected side was observed in the experimental group, compared with the control group (P<0.01).ConclusionsMatriderm enables effective healing and improves elasticity in treatment of patients with diabetic foot ulcer.

Retrospective analysis of 56 soft tissue defects treated with one‐stage reconstruction using dermal skin substitutes

“…By now, there have also been first reports of dermal skin substitutes used in a one‐step procedure with split‐thickness skin grafting in reconstructive surgery of soft tissue injuries associated with exposed tendons and/or denuded bone . However, given the small number of patients published to date, we would like to share our experience with 56 consecutive patients . Moreover, the successful use of Matriderm ® matrix in a one‐step procedure in two patients is presented in more detail.…”

Failure rates of artificial dermis products in treatment of diabetic foot ulcer: A systematic review and network meta‐analysis

“…The relative risk of failure ranged between 3 and 100%, indicating that artificial dermis products have failure rates that were very low or similar to nonartificial products in different studies (Table ). Further two studies reported 70 24 and 100% higher relative risk of failure in the intervention group, as compared to control groups. In second phase analysis, all three studies (with similar cohort characteristics) presented a low failure rate and statistically significant complete reepithelialization rates .…”

“…Further two studies reported 70 24 and 100% higher relative risk of failure in the intervention group, as compared to control groups. In second phase analysis, all three studies (with similar cohort characteristics) presented a low failure rate and statistically significant complete reepithelialization rates . All of the studies complete reepithelialization rates demonstrated statistical significance.…”

Therapeutic strategies for skin regeneration based on biomedical substitutes

“…The biomaterials used to produce acellular skin substitutes can also be animal‐derived, obtaining acellular xenografts such as Matriderm ® , which is based on a bovine matrix of collagen type I and elastin and is employed for dermal regeneration . This skin substitute shows an improved vascularization and elasticity of the regenerated tissue . It is indicated for the treatment of deep dermal defects, such as partial and full‐thickness burn injuries, reconstructive wounds and surgical wounds (congenital defects or excision of skin cancer) …”